During the conference, “Biomarkers as a tool for detecting cervical cancer”, health specialists agreed that the Preventix test is a viable alternative for the timely detection of cervical cancer.
During the conference, the medical director of MAC Hospitals CDMX, Marco Toledo and the general director of MAC Hospitals CDMX, Gabriel Ayerdi, announced that they will be the first to have and implement the Preventix test in their hospitals.
At the event, doctors specialized in the subject, explained that this disease affects hundreds of thousands of women in Mexico each year, so it is essential to face it in the most effective way possible and highlighted the contribution that Timser has made to detect this type of cancer.
In turn, Denisse Acuña González, obstetrician-gynecologist, explained that cervical cancer is not detected in time and to a great extent, this is due to a great lack of information and education.
“Education in the population is a priority that we must all do, especially those populations that are in the developing world or in indigenous communities where a sexual life begins at a very early age,” she said.
For his part, Dr. David Cantú, Research Director of the National Cancer Institute, pointed out that this disease is not generated from one day to the next, but takes a long time to develop, approximately 10 to 20 years, which is why it is possible to prevent it one hundred percent.
To achieve this, Dr. Ruth Esparza mentioned the importance of biomarkers as an early detection method for cervical cancer.
“A biomarker is a biomolecule. What it does is to detect what is happening in a process, whether in a pathology such as cancer or diabetes, and to know that we can find it in time,” she explained.
Eduardo Cervera Cevallos, director of teaching at the National Cancer Institute, stated that with Preventix it is possible to detect precancerous lesions and cancer itself, with just a drop of blood.
Approximately 70 percent of the cases are invisible, so the disease is not detected until it is already advanced.
“The treatment of a woman in stage zero is very low cost. However, in stage three, treatment costs between two or three million pesos. This can be avoided by detecting it earlier or, in fact, preventing it from the beginning. […] We want to send cancer down a tube”, he concluded.